Literature DB >> 23240715

Standardization of Gleason grading among 337 European pathologists.

Lars Egevad1, Amar S Ahmad, Ferran Algaba, Daniel M Berney, Liliane Boccon-Gibod, Eva Compérat, Andrew J Evans, David Griffiths, Rainer Grobholz, Glen Kristiansen, Cord Langner, Antonio Lopez-Beltran, Rodolfo Montironi, Sue Moss, Pedro Oliveira, Ben Vainer, Murali Varma, Philippe Camparo.   

Abstract

AIMS: The 2005 International Society of Urological Pathology (ISUP) modification of Gleason grading recommended that the highest grade should always be included in the Gleason score (GS) in prostate biopsies. We analysed the impact of this recommendation on reporting of GS 6 versus 7. METHODS AND
RESULTS: Fifteen expert uropathologists reached two-thirds consensus on 15 prostate biopsies with GS 6-7 cancer. Eighty-five microphotographs were graded by 337 of 617 members of the European Network of Uropathology (ENUP), representing 19 countries. There was agreement between expert and majority member GS in 12 of 15 cases, while members upgraded in three cases. Among members and the expert consensus, a GS >6 was assigned by 64.5% and 60%, respectively. Mean member GS was higher than consensus GS in nine of 15 cases. A Gleason pattern (GP) 5 was reported by 0.3-5.6% in 10 cases. Agreement between consensus and member GS was 58.2-89.3% (mean 71.4%) in GS 6 cases and 46.3-63.8% (mean 56.4%) in GS 7 cases (P = 0.009).
CONCLUSIONS: While undergrading of prostate cancer used to be prevalent, some now tend to overgrade. Minimum diagnostic criteria for GP 4 and 5 in biopsies need to be better defined. Image libraries reviewed by experts may be useful for standardization.
© 2012 Blackwell Publishing Limited.

Entities:  

Mesh:

Year:  2013        PMID: 23240715     DOI: 10.1111/his.12008

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  50 in total

1.  Interpathologist concordance in the histological diagnosis of focal prostatic atrophy lesions, acute and chronic prostatitis, PIN, and prostate cancer.

Authors:  Francesca Giunchi; Kristina Jordahl; Enrico Bollito; Maurizio Colecchia; Carlo Patriarca; Antonietta D'Errico; Francesco Vasuri; Deborah Malvi; Alessandro Fornari; Luca Reggiani Bonetti; Barbara Corti; Mauro Papotti; Paolo DeGiuli; Massimo Loda; Rodolfo Montironi; Michelangelo Fiorentino; Jennifer R Rider
Journal:  Virchows Arch       Date:  2017-04-12       Impact factor: 4.064

2.  Open-Top Light-Sheet Microscopy Image Atlas of Prostate Core Needle Biopsies.

Authors:  Nicholas P Reder; Adam K Glaser; Erin F McCarty; Ye Chen; Lawrence D True; Jonathan T C Liu
Journal:  Arch Pathol Lab Med       Date:  2019-03-20       Impact factor: 5.534

3.  Handling and reporting of transperineal template prostate biopsy in Europe: a web-based survey by the European Network of Uropathology (ENUP).

Authors:  Solene-Florence Kammerer-Jacquet; Eva Compérat; Lars Egevad; Ondra Hes; Jon Oxley; Murali Varma; Glen Kristiansen; Daniel M Berney
Journal:  Virchows Arch       Date:  2018-01-11       Impact factor: 4.064

4.  Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer.

Authors:  Charlotte F Kweldam; Intan P Kümmerlin; Daan Nieboer; Ewout W Steyerberg; Chris H Bangma; Luca Incrocci; Theodorus H van der Kwast; Monique J Roobol; Geert J van Leenders
Journal:  Mod Pathol       Date:  2017-05-19       Impact factor: 7.842

5.  YRNA expression in prostate cancer patients: diagnostic and prognostic implications.

Authors:  Yuri Tolkach; Eva-Maria Niehoff; Anna Franziska Stahl; Chenming Zhao; Glen Kristiansen; Stefan C Müller; Jörg Ellinger
Journal:  World J Urol       Date:  2018-02-28       Impact factor: 4.226

6.  Multiview boosting digital pathology analysis of prostate cancer.

Authors:  Jin Tae Kwak; Stephen M Hewitt
Journal:  Comput Methods Programs Biomed       Date:  2017-02-22       Impact factor: 5.428

7.  Diagnostic prostate biopsy performed in a non-academic center increases the risk of re-classification at confirmatory biopsy for men considering active surveillance for prostate cancer.

Authors:  L M Wong; S Ferrara; S M H Alibhai; A Evans; T Van der Kwast; G Trottier; N Timilshina; A Toi; G Kulkarni; R Hamilton; A Zlotta; N Fleshner; A Finelli
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-12-09       Impact factor: 5.554

Review 8.  Defining the threshold for significant versus insignificant prostate cancer.

Authors:  Theo H Van der Kwast; Monique J Roobol
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

9.  Active surveillance for the management of localized prostate cancer: Guideline recommendations.

Authors:  Chris Morash; Rovena Tey; Chika Agbassi; Laurence Klotz; Tom McGowan; John Srigley; Andrew Evans
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

10.  [Objective grading of prostate carcinoma based on fractal dimensions: Gleason 3 + 4= 7a ≠ Gleason 4 + 3 =7b].

Authors:  P Waliszewski; F Wagenlehner; S Kribus; W Schafhauser; W Weidner; S Gattenlöhner
Journal:  Urologe A       Date:  2014-10       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.